Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $11.00.

Several research analysts have commented on AQST shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Leerink Partners boosted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target for the company.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new stake in Aquestive Therapeutics during the 2nd quarter valued at about $594,000. Financial Advocates Investment Management lifted its position in Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after purchasing an additional 14,000 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at approximately $254,000. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $27,000. Finally, PFG Investments LLC grew its holdings in shares of Aquestive Therapeutics by 22.9% in the second quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after purchasing an additional 11,000 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST opened at $3.52 on Friday. The stock has a market capitalization of $320.95 million, a PE ratio of -7.82 and a beta of 2.63. Aquestive Therapeutics has a one year low of $1.95 and a one year high of $6.23. The business’s fifty day moving average price is $4.66 and its 200-day moving average price is $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period last year, the company earned ($0.03) EPS. As a group, equities analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.